Business
Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants
Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants.
About this update from Avivagen, Inc.
[{"type":"text","content":"Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to extend the expiry date of certain of its outstanding warrants. The extended warrants are exercisable to purchase 2,774,991 common shares at $0.90 per share. These warrants were issued by Avivagen on June 1, 2016 by way of a private placement and had also been set to expire on March 31, 2020. The new expiry date for these warrants is September 30, 2020.All other terms and conditions of the warrants remain unchanged. The Company’s intention to seek extension of these warrants was previously announced on March 4, 2020.About AvivagenAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture and OTCQB® Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release. About OxC-beta™ Technology and OxC-beta™ LivestockAvivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico,Taiwan, New Zealand, Thailand, Australia and Malaysia.Avivagen’s OxC-beta™ Livestock product is safe, effective and coul...